COVID-19 has severely disrupted pharma and medtech R&D. Leaders should prepare along three horizons—safeguarding patients and employees, adapting operations for a recovery, and building for the next normal.
COVID-19 implications for life sciences R&D: Recovery and the next normal
No comments:
Post a Comment